IONS - Ionis Pharmaceuticals Inc. (IONS) Q1 2024 Earnings Call Transcript

2024-05-07 17:39:09 ET

Ionis Pharmaceuticals, Inc. (IONS)

Q1 2024 Results Conference Call

May 07, 2024 11:30 AM ET

Company Participants

Wade Walke - SVP of IR

Brett Monia - CEO

Kyle Jenne - Chief Global Product Strategy Officer

Beth Hougen - CFO

Richard Geary - Chief Development Officer

Eric Swayze - EVP of Research

Eugene Schneider - Chief Clinical Development Officer

Jonathan Birchall - Chief Commercial Officer

Conference Call Participants

Debjit Chattopadhyay - Guggenheim Securities

Gary Nachman - Raymond James

Jessica Fye - JPMorgan

Joseph Stringer - Needham & Company

Jason Gerberry - Bank of America

Yanan Zhu - Wells Fargo

Luca Issi - RBC

David Lebowitz - Citi

Kostas Biliouris - BMO

Presentation

Operator

Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.

Wade Walke

Thank you, Keith. Before we begin, I encourage everyone to go to the Investors section of the Ionis Web site to view the press release and the related financial tables we will be discussing today, including the reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our Web site that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer. Richard Geary, our Chief Development Officer; Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Jonathan Birchall, Chief Commercial Officer, will also join us for the Q&A portion of the call. I would like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning, everybody, and thanks for joining us today. 2024 is off to a great start for Ionis as we continue to execute on our vision to bring better futures to people with serious diseases. With the recent US launch of our first Ionis co-branded medicine, WAINUA, Ionis discovered medicines are now reaching even more people living with serious diseases. And we're on the cusp of independently delivering a steady stream of new transformational medicines to patients beginning with our planned launches of olezarsen and donidalorsen. By uniting groundbreaking science and technology with a relentless passion to discover, develop and deliver new transformational medicines to people in need, we believe Ionis is well positioned to unlock next level value. Renewal launch for ATTR polyneuropathy is on track in the US with our co-commercialization partner, AstraZeneca. While it's early days in the launch, we're pleased with the collective team's progress. With approval decisions in Europe and Canada expected later this year and additional regulatory submissions already completed, we expect to soon bring WAINUA to even more patients around the globe. And based on WAINUA’s strong efficacy profile, together with the freedom of simple at-home monthly self-administration, we believe WAINUA is poised to become the therapy of choice for ATTR patients. We continue to advance our CARDIO-TTRansform study of WAINUA for the larger ATTR cardiomyopathy indication with the potential for data as early as 2025. As the largest study ever conducted in this patient population, the landmark CARDIO-TTRansform trial is on track to deliver the most comprehensive and robust data set. We expect the data we generate will enable physicians and payers to make informed treatment decisions in this dynamic treatment landscape. And with AstraZeneca's global leadership in the commercialization of novel cardiovascular treatments, coupled with our leadership in TTR amyloidosis, we believe we are well positioned to bring WAINUA patients in the US and around the globe....

For further details see: